Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor

Cancer Research

Volumn 61, Issue 16, 2001, Pages 6131-6136

  Lal, Geeta ^a   Ash, Colleen ^a   Hay, Kazy ^a   Gallinger, Steven ^a   Redston, Mark ^b   Mak, Tak ^c   Kwong, Elizabeth ^d   Hancock, Bruno ^d   Kargman, Stacia ^d   Evans, Jilly F ^e  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; CANCER RISK; COLON ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; INTESTINE CANCER; INTESTINE POLYP; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOMA; ANIMALS; COLORECTAL NEOPLASMS; CROSSES, GENETIC; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DNA REPAIR; DNA-BINDING PROTEINS; FEMALE; FURANS; GENES, APC; INTESTINAL POLYPS; ISOENZYMES; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTS HOMOLOG 2 PROTEIN; PRECANCEROUS CONDITIONS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTO-ONCOGENE PROTEINS; SUBSTRATE SPECIFICITY; SULINDAC;

EID: 0035881311     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II)
2. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention
3. Sulindac causes regression of rectal polyps in familial adenomatous polyposis
4. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
5. COX-2 inhibitors
6. Aspirin, NSAIDs, and colon cancer prevention. Mechanisms?
7. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey and human gastrointestinal tracts
8. Distribution of COX-1 and COX-2 in normal and inflamed tissues
9. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing
10. Structure of the mitogen-inducible TIS 10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase
11. Human cyclooxygenase-2 cDNA
12. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
13. Cyclooxygenase in biology and disease
14. Overview - Mechanisms of actions of anti-inflammatory drugs
15. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production
16. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2
17. Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1
18. Selective inhibition of inducible cyclooxygenase-2 in vivo is antiinflammatory and nonulcerogenic
19. Prostaglandin endoperoxide synthase: Why two isoforms?
20. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
21. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
22. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors
23. Elevated cyclooxygenase-2 levels in Min mouse adenomas
24. Cellular localization of cyclo-oxygenase isozymes in Crohn's disease and colorectal cancer
25. Δ716 knockout mice by inhibition of cyclooxygenase 2 (Cox- 2)
26. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
27. Δ716 mouse by Rofecoxib, a specific cyclooxygenase-2 inhibitor
28. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma
29. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas
30. Host cyclooxygenase-2 modulates carcinoma growth
31. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase-2 specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
32. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis
33. Chemoprevention activity of celecoxib, a specific cyclooxygenase-2 inhibitor against colon carcinogenesis
34. Sulindac suppresses tumorigenesis in the Min mouse
35. min mouse model by the nonsteroidal anti-inflammatory drug piroxicam
36. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
37. Aspirin prevents tumors in a murine model of familial adenomatous polyposis
38. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coil Min mouse model with aspirin
39. The sulfide metabolite of sulindac prevents tumors and restores enterocycte apoptosis in a murine model of familial adenomatous polyposis
40. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis
41. MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis
42. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse
43. + from all tumor lineages
44. MSH2 deficient mice are viable and susceptible to lymphoid tumors
45. Spontaneous intestinal carcinoma and skin neoplasms in Msh2-deficient mice
46. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors
47. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
48. Malignant transformation and antineoplastic action of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblast
49. Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection
50. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2
51. The effects of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
52. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer
53. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer
54. Reduced COX-2 protein in colorectal cancer with defective mismatch repair
55. Combinations for cancer prevention